tbuckley/cabot-search huggingface dataset:
P2.02-003 Increased Circulating Cytokeratin-19 (Cyfra 21-1) is Predictive of Poor Outcome of Locally Advanced Squamous Cell Carcinoma in Lung
Authors: Jingbo Wang, Zhe Ji, Jianzhong Cao, Yan Ma, Wei Jiang, Lipin Liu, Yu Men, Cai Xu, Xiaozhen Wang, Zhou Guang Hui, Jun Liang, Jima Lv, Zongmei Zhou, Zefen Xiao, Qinfu Feng, Dongfu Chen, Hongxing Zhang, Weibo Yin, Luhua Wang
Journal: Journal of Thoracic Oncology (2017)
OA02.07 Characterization of the Tumor Microenvironment and Investigation of Immune Checkpoint Expression in Malignant Pleural Mesothelioma
Authors: Elly Marcq, Vasiliki Siozopoulou, Jorrit De Waele, Jonas Van Audenaerde, Karen Zwaenepoel, Eva Santermans, Niel Hens, Patrick Pauwels, Jan Van Meerbeeck, Evelien Smits
Journal: Journal of Thoracic Oncology (2017)
Clinical Characteristics of Classic Paroxysmal Nocturnal Hemoglobinuria (PNH) in Pediatric Patients: A Comparison with Classic PNH in Adults. An International PNH Registry Study
Authors: Alvaro Urbano-Ispizua, Hubert Schrezenmeier, Petra Muus, Jaroslaw P Maciejewski, Gérard Socié, Jeffrey Szer, Robert A. Brodsky, Monica Bessler, Wendell F Rosse, Yuzuru Kanakura, Gus Khursigara, Camille L Bedrosian, Peter Hillmen
Journal: Blood (2011)
Differential Signaling through p190 and p210 Forms of BCR-ABL Fusion Proteins Revealed By Proteomic Analysis
Authors: Jevon Cutler, Rahia Tahir, Jingnan Han, Raja Sekhar Nirujogi, Tai-Chung Huang, Xianrong Wong, Saradhi Mallampati, Xiaoping Sun, Patrick Brown, Karen Reddy, Akhilesh Pandey
Journal: Blood (2015)
MA16.06 Phase I/II Study of AC0010, Mutant-Selective EGFR Inhibitor, in Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR T790M Mutation
Authors: Yi Long Wu, Qing Zhou, Xiaoqing Liu, Li Zhang, Jianying Zhou, Lin Wu, Tongtong An, Ying Cheng, Xin Zheng, Bei Hu, Ji Jiang, Xin Fang, Wanhong Xu, Xiao Xu
Journal: Journal of Thoracic Oncology (2017)
Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs)
Authors: Antonio Almeida, Valeria Santini, Stefanie Gröpper, Anna Jonasova, Norbert Vey, Aristoteles Giagounidis, Eva Hellström-Lindberg, Ghulam J. Mufti, Guillermo Sanz, Barry Skikne, Albert Hoenekopp, Francis Séguy, Jianhua Zhong, Pierre Fenaux
Journal: Blood (2015)
P1.01-032 Emergency Department Visits by Lung Cancer Patients in Korea
Authors: Dong Won Park, Gun Woo Koo, Tai Sun Park, Ji-Yong Moon, Sang-Heon Kim, Tae-Hyung Kim, Dong Ho Shin, Ho Joo Yoon, Jang Won Sohn
Journal: Journal of Thoracic Oncology (2017)
OA12.03 Percutaneous Cryoablation for Lung Cancer Patients for Whom Surgery or Radiotherapy is Contraindicated Due to Idiopathic Pulmonary Fibrosis
Authors: Takashi Ohtsuka, Keisuke Asakura, Kyohei Masai, Kaoru Kaseda, Ikuo Kamiyama, Masanori Inoue, Seishi Nakatsuka, Hisao Asamura
Journal: Journal of Thoracic Oncology (2017)
Improvement of Concurrent Autoimmune Diseases Following Reduced-Intensity Stem Cell Transplantation (RIST) for Hematological Disorders: Graft-Versus Autoimmunity (GVA) Effect.
Authors: Koichiro Yuji, Masahiro Kami, Daisuke Kato, Yuji Miura, Tomohiro Myojo, Eiji Kusumi, Hiroto Narimatsu, Yukiko Kishi, Tamae Hamaki, Tomoko Matsumura, Shigesaburo Miyakoshi, Junichi Ueyama, Shinichi Morinaga, Yoichi Takaue, Shuichi Taniguchi
Journal: Blood (2004)
P138 An innovative approach to study design: using electronic medical records to inform the feasibility and design of the novelty study (a novel observational longitudinal study on patients with asthma and/or COPD)
Authors: HK Reddel, M Gerhardsson de Verdier, A Agustí, R Beasley, EH Bel, C Janson, B Make, RJ Martin, I Pavord, D Postma, D Price, C Keen, A Gardev, S Rennard, A Sveréus, AT Bansal, L Brannman, N Karlsson, J Nuevo, F Nyberg, S Young, J Vestbo
Journal: Thorax (2016)

<h3>Introduction</h3> Asthma and COPD have traditionally been viewed as distinct diseases. While they have overlapping biological mechanisms, past studies often focused on specific aspects of each disease based on a single diagnostic label, and many clinical trial populations were defined by strict enrolment criteria with limited generalisability. NOVELTY is a prospective, multinational, observational, longitudinal cohort study aiming to enrol 14,800 patients aged ≥12 years with a diagnosis or suspected diagnosis of asthma and/or COPD. In this population, the objectives of NOVELTY are to: (i) describe patient characteristics, treatment patterns and burden of illness over time in clinical practice; and (ii) use biomarkers and clinical parameters to identify phenotypes and endotypes associated with differential outcomes for symptom burden, clinical evolution and healthcare utilisation. <h3>Aim</h3> This feasibility analysis of electronic medical records (EMRs) aimed to understand the potential study population, assess patient numbers across disease severities and evaluate EMRs as a data source for NOVELTY. <h3>Methods</h3> EMRs from patients with asthma and/or COPD were identified from national databases covering primary and specialist care in 11 countries (Table). Disease severity was classified using treatment- and/or lung function-based algorithms for asthma and COPD. EMR variable coverage and completeness were assessed for standardised clinical, laboratory and physiological data and patient-reported outcomes (PROs). <h3>Results</h3> EMRs for 921,888 patients with asthma, 958,945 with COPD and 117,893 with both diagnoses were identified. EMRs routinely documented patient demographics and characteristics, but many disease- and treatment-related data, and PROs/symptoms required for evaluation of disease severity and clinical outcomes were frequently missing (not collected or not documented; Table). Disease severity could not be classified in 561,837 patients (asthma) and 355,743 patients (COPD), representing 22−100% and 7−85% of patients across countries. <h3>Conclusions</h3> EMR analysis revealed numbers of patients per country potentially eligible for NOVELTY. Many variables required to meet NOVELTY objectives were missing in EMRs (e.g. lung function and PRO/symptoms); therefore, variables in NOVELTY will primarily be documented in electronic case report forms, not EMRs. The lack of lung function data in many countries suggested divergences in diagnosis of asthma/COPD between clinical guidelines (which include lung function tests) and clinical practice.
P1.02-031 Mutations in TP53, PIK3CA, PTEN and Other Genes in EGFR Mutated Lung Cancers: Correlation with Clinical Outcomes
Authors: Paul Vanderlaan, Deepa Rangachari, Susan Mockus, Vanessa Spotlow, Honey Reddi, Joan Malcom, Mark Huberman, Loren Joseph, Susumu Kobayashi, Daniel Costa
Journal: Journal of Thoracic Oncology (2017)
Moving Biomarkers toward Clinical Implementation in Kidney Transplantation
Authors: Madhav C. Menon, Barbara Murphy, Peter S. Heeger
Journal: Journal of the American Society of Nephrology (2017)

Long-term kidney transplant outcomes remain suboptimal, delineating an unmet medical need. Although current immunosuppressive therapy in kidney transplant recipients is effective, dosing is conventionally adjusted empirically on the basis of time after transplant or altered in response to detection of kidney dysfunction, histologic evidence of allograft damage, or infection. Such strategies tend to detect allograft rejection after significant injury has already occurred, fail to detect chronic subclinical inflammation that can negatively affect graft survival, and ignore specific risks and immune mechanisms that differentially contribute to allograft damage among transplant recipients. Assays and biomarkers that reliably quantify and/or predict the risk of allograft injury have the potential to overcome these deficits and thereby, aid clinicians in optimizing immunosuppressive regimens. Herein, we review the data on candidate biomarkers that we contend have the highest potential to become clinically useful surrogates in kidney transplant recipients, including functional T cell assays, urinary gene and protein assays, peripheral blood cell gene expression profiles, and allograft gene expression profiles. We identify barriers to clinical biomarker adoption in the transplant field and suggest strategies for moving biomarker-based individualization of transplant care from a research hypothesis to clinical implementation.
Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis
Authors: Celine Lefebvre, Thomas Bachelot, Thomas Filleron, Marion Pedrero, Mario Campone, Jean-Charles Soria, Christophe Massard, Christelle Lévy, Monica Arnedos, Magali Lacroix-Triki, Julie Garrabey, Yannick Boursin, Marc Deloger, Yu Fu, Frédéric Commo, Véronique Scott, Ludovic Lacroix, Maria Vittoria Dieci, Maud Kamal, Véronique Diéras, Anthony Gonçalves, Jean-Marc Ferrerro, Gilles Romieu, Laurence Vanlemmens, Marie-Ange Mouret Reynier, Jean-Christophe Théry, Fanny Le Du, Séverine Guiu, Florence Dalenc, Gilles Clapisson, Hervé Bonnefoi, Marta Jimenez, Christophe Le Tourneau, Fabrice André
Journal: PLoS Medicine (2016)

Major advances have been achieved in the characterization of early breast cancer (eBC) genomic profiles. Metastatic breast cancer (mBC) is associated with poor outcomes, yet limited information is available on the genomic profile of this disease. This study aims to decipher mutational profiles of mBC using next-generation sequencing.Whole-exome sequencing was performed on 216 tumor-blood pairs from mBC patients who underwent a biopsy in the context of the SAFIR01, SAFIR02, SHIVA, or Molecular Screening for Cancer Treatment Optimization (MOSCATO) prospective trials. Mutational profiles from 772 primary breast tumors from The Cancer Genome Atlas (TCGA) were used as a reference for comparing primary and mBC mutational profiles. Twelve genes (TP53, PIK3CA, GATA3, ESR1, MAP3K1, CDH1, AKT1, MAP2K4, RB1, PTEN, CBFB, and CDKN2A) were identified as significantly mutated in mBC (false discovery rate [FDR] < 0.1). Eight genes (ESR1, FSIP2, FRAS1, OSBPL3, EDC4, PALB2, IGFN1, and AGRN) were more frequently mutated in mBC as compared to eBC (FDR < 0.01). ESR1 was identified both as a driver and as a metastatic gene (n = 22, odds ratio = 29, 95% CI [9-155], p = 1.2e-12) and also presented with focal amplification (n = 9) for a total of 31 mBCs with either ESR1 mutation or amplification, including 27 hormone receptor positive (HR+) and HER2 negative (HER2-) mBCs (19%). HR+/HER2- mBC presented a high prevalence of mutations on genes located on the mechanistic target of rapamycin (mTOR) pathway (TSC1 and TSC2) as compared to HR+/HER2- eBC (respectively 6% and 0.7%, p = 0.0004). Other actionable genes were more frequently mutated in HR+ mBC, including ERBB4 (n = 8), NOTCH3 (n = 7), and ALK (n = 7). Analysis of mutational signatures revealed a significant increase in APOBEC-mediated mutagenesis in HR+/HER2- metastatic tumors as compared to primary TCGA samples (p < 2e-16). The main limitations of this study include the absence of bone metastases and the size of the cohort, which might not have allowed the identification of rare mutations and their effect on survival.This work reports the results of the analysis of the first large-scale study on mutation profiles of mBC. This study revealed genomic alterations and mutational signatures involved in the resistance to therapies, including actionable mutations.
P128 Comparison of safety and efficacy of airway clearance techniques, hypertonic saline and bronchoscopy in a severe asthma service
Authors: RL Sheehan, RM Niven, DM Ryan
Journal: Thorax (2016)

<h3>Introduction</h3> There is limited research into airway clearance techniques (ACT) and high dose hypertonic saline 7% (HS-7) tolerance and safety in adults with severe asthma. Clinical benefit of sputum eosinophils and microbiology in severe asthma is well established. Airway samples can be obtained via spontaneous production, using physiotherapy (ACT, sputum induction (0.9–4.5% traditionally) or via bronchoscope.<sup>1</sup> There are concerns with regards to risk of asthma exacerbation with sputum induction and bronchoscopy. <h3>Objective</h3> assess and compare safety and efficacy of ACT, HS-7 and bronchoscopy in patients attending severe asthma clinic. <h3>Method</h3> We assessed consecutive patients attending a severe asthma service at a tertiary referral centre who had undergone ACT and or HS-7 challenge and or bronchoscopy during 2014–2016. In total, 330 procedures were performed by a chest physiotherapist (ACT/HS-7) and consultant respiratory physician (bronchoscopy). Data was gathered on procedure tolerance and sample yield. Indications for undergoing HS-7 included sample procurement or challenge test for home nebulisation. Bronchoscopy was performed for a variety of indications, not limited solely to sample procurement. <h3>Results</h3> 114 patients completed ACT, 109 underwent HS-7 and 99 had bronchoscopy (Table 1). 65 of 104 (62.5%) in the physiotherapy group had no prior spontaneous sputum samples. Of these, 46 (71%) had HS-7 induction and 19 (29%) had successful ACT. 25 of 77 (32%) patients in the physiotherapy group had positive bacterial culture, and 18 of 38 (47%) positive aspergillus PCR. ACT, HS-7 and bronchoscopy were well tolerated. All 114 (100%) patients tolerated ACT from an asthma perspective. 8 of 117 (7%) of HS-7 group and 8 of 99 (8%) of bronchoscopy group required rescue salbutamol nebulisation without further complications. Two patients had severe asthma exacerbations in the bronchoscopy group, 2 of 99 (2%), and required hospitalisation at ward level, This risk was similar to previously reported data. <h3>Conclusion</h3> In patients attending a severe asthma clinic physiotherapy techniques (ACT and HS-7) were safe and effective. Bronchoscopy had similar requirement for rescue salbutamol nebulisation compared to HS-7, but a higher risk (2%) of severe asthma exacerbation. <h3>Reference</h3> Brinke AT, <i>et al</i>. Sputum induction in severe asthma by standardised protocol. <i>AJRCCM</i> 2001;<b>164</b>(5):749–753.
MA17.09 Premature Fibroblast Senescence in Large Cell Carcinoma Provides Enhanced Growth and Invasive Advantages to Cancer Cells in Culture and in vivo
Authors: Roberto Lugo, Marta Gabasa, Francesca Andriani, Marta Puig, Federica Facchinetti, Josep Ramírez, Abel Gómez-Caro, Pere Gascón, Albert Davalos, Noemi Reguart, Luca Roz, Jordi Alcaraz
Journal: Journal of Thoracic Oncology (2017)
Up-front melphalan in Ewing's family tumors with bone/bone marrow metastases at onset (very-high risk EFTs). A report from ISG/AIEOP “Very High Risk EFTs Cooperative Study”
Authors: R. Luksch, F. Fagioli, E. Grignani, S. Aliberti, M. Casanova, G. Hanau, A. Tamburini, A. Prete, S. Ferrari, P. Picci
Journal: Journal of Clinical Oncology (2004)

9037 Background:Patients with very-high risk EFTs have a poor prognosis. Melphalan (L-PAM) has been widely used in myeloablative regimens in EFTs, without a prior demonstration of its effectiveness in this disease. Methods: From March 2001, a study was opened for very-high risk EFTs with the main aim to investigate the activity and toxicity of up-front L-PAM at non myeloablative doses. Treatment consisted of initial window-therapy with L-PAM (50 mg/m2 every 21 days × 2 courses) followed by 8 intensive chemotherapy courses, and consolidation with megatherapy+autologous PBSC rescue. PBSC collection was scheduled in responders after the 4th/6th chemotherapy course. Surgery and radiotherapy were employed on individual basis Results: As of September 2003, 17 consecutive patients (median age 16yrs, range 9–34) were enrolled. All patients were evaluable for toxicity and up-front L-PAM activity. No severe toxicities were reported, but for grade 3–4 hemopoietic toxicity. After L-PAM courses, grade 4 neutropenia, thrombocytopenia, anemia were registered in 76%, 68%, and 41% of cases, respectively. Responses after the up-front phase according to the RECIST criteria were as follows: 13/17 (76%) PR, 2/17 (12%) SD, 2/17 (12%) PD. Up to date 13 patients were evaluable for PBSC collection. Ten/13 (77%) mobilized PBSC adequately, and the median harvest was 5 × 106 CD34+/kg (range 2.6 –15 × 106). Conclusions: L-PAM proved to be active. Toxicity was predictable and manageable. Moreover, the scheduled L-PAM doses allowed PBSC collection even after further intensive chemotherapy in most cases. No significant financial relationships to disclose.
P2.01-060 Comparative Analysis of PD-L1 Expression between Circulating Tumor Cells and Tumor Tissues in Patients with Lung Cancer
Authors: Yasuhiro Koh, Satomi Yagi, Hiroaki Akamatsu, Ayaka Tanaka, Kuninobu Kanai, Atsushi Hayata, Nahomi Tokudome, Keiichiro Akamatsu, Masayuki Higuchi, Hisashige Kanbara, Hiroki Ueda, Masanori Nakanishi, Nobuyuki Yamamoto
Journal: Journal of Thoracic Oncology (2017)
P1.02-074 The Gene Expression Signatures of Pulmonary Adenocarcinoma with Micropapillary Features
Authors: Yuki Sata, Takahiro Nakajima, Keisuke Matsusaka, Masaki Fukuyo, Junichi Morimoto, Yuichi Sakairi, Taiki Fujiwara, Hironobu Wada, Hidemi Suzuki, Takekazu Iwata, Masako Chiyo, Atsushi Kaneda, Ichiro Yoshino
Journal: Journal of Thoracic Oncology (2017)
Portography: a potentially fatal complication during endoscopic ultrasound-guided choledochoduodenostomy
Authors: Gianfranco Donatelli, Jean-Loup Dumont, Stavros Dritsas, Thierry Tuszynski, Bertrand Vergeau, Bruno Meduri
Journal: Endoscopy (2017)

Endoscopic ultrasound (EUS)-guided choledochoduodenostomy (EUS-CDS) is a safe alternative to transhepatic cholangiography when endoscopic retrograde cholangiopancreatography (ERCP) has failed or in patients with altered anatomy [1]. There are however several adverse events that can be life-threatening in some circumstances [1] [2].
P3.02b-039 Analysis of Prognostic Factor for Afatinib Treated Patients with EGFR Mutation Positive NSCLC
Authors: Masafumi Sata, Terufumi Kato, Saki Manabe, Shuji Murakami, Tetsuro Kondo, Haruhiro Saito, Akimasa Sekine, Takashi Ogura, Kouzo Yamada
Journal: Journal of Thoracic Oncology (2017)
Secondary Malignancies in CML Patients – Data From the German CML Study IV
Authors: Manuel Barreto Miranda, Michael Lauseker, Ulrike Proetel, Annette Schreiber, Benjamin Hanfstein, Gabriela M. Baerlocher, Dominik Heim, Gerhard Ehninger, Dieter K. Hossfeld, Hans-Jochem Kolb, Stefan W. Krause, Christoph Nerl, Hermann Einsele, Mathias Hänel, Jolanta Dengler, Christiane Falge, Lothar Kanz, Andreas Neubauer, Michael Kneba, Frank Stegelmann, Michael Pfreundschuh, Cornelius F. Waller, Karsten Spiekermann, Wolf-Karsten Hofmann, Martin C. Müller, Markus Pfirrmann, Andreas Hochhaus, Joerg Hasford, Rüdiger Hehlmann, Susanne Saussele
Journal: Blood (2012)
Survivin Regulates Aberrant Proliferation of Hematopoietic Progenitor Cells with Self Renewal Capability and Development of Acute Leukemia Induced by Internal-Tandem-Duplication of Flt3.
Authors: Seiji Fukuda, Pratibha Sigh, Edward M. Conway, Seiji Yamaguchi, Louis M. Pelus
Journal: Blood (2007)
P1.07-014 Impact of Chemotherapy for Small Cell Lung Cancer in the Third Line and beyond, a SEER-MEDICARE Analysis
Authors: Sungjin Kim, Camille Ragin, Zhengjia Chen, Madhusmita Behera, Rathi Pillai, Conor Steuer, Chandra Belani, Fadlo Khuri, Suresh Ramalingam, Taofeek Owonikoko
Journal: Journal of Thoracic Oncology (2017)
A manifesto for reproducible science
Authors: Marcus R. Munafò, Brian A. Nosek, Dorothy V. M. Bishop, Katherine S. Button, Christopher D. Chambers, Nathalie Percie du Sert, Uri Simonsohn, Eric-Jan Wagenmakers, Jennifer J. Ware, John P. A. Ioannidis
Journal: Nature Human Behaviour (2017)

Abstract Improving the reliability and efficiency of scientific research will increase the credibility of the published scientific literature and accelerate discovery. Here we argue for the adoption of measures to optimize key elements of the scientific process: methods, reporting and dissemination, reproducibility, evaluation and incentives. There is some evidence from both simulations and empirical studies supporting the likely effectiveness of these measures, but their broad adoption by researchers, institutions, funders and journals will require iterative evaluation and improvement. We discuss the goals of these measures, and how they can be implemented, in the hope that this will facilitate action toward improving the transparency, reproducibility and efficiency of scientific research.
P2.01-093 Exo-ALK Proof of Concept: Exosomal Analysis of ALK Alterations in Advanced NSCLC Patients
Authors: Christian Rolfo, Jean François Laes, Pablo Reclusa, Anna Valentino, Maxime Lienard, Ignacio Gil-Bazo, Umberto Malapelle, Rafael Sirera, Danilo Rocco, Jan Van Meerbeeck, Patrick Pauwels, Marc Peeters
Journal: Journal of Thoracic Oncology (2017)
P2.01-015 Differentially Expressed microRNAs in Lung Adenocarcinoma Invert Effects of Copy Number Aberrations of Prognostic Genes
Authors: Tomas Tokar, Emily Vucic, Chiara Chiara Pastrello, Varune Ramnarine, Chang-Qi Zhu, Kenneth Craddock, Frances Shepherd, Ming Tsao, Wan Lam, Igor Jurisica
Journal: Journal of Thoracic Oncology (2017)
P3.02b-030 Single Institution Experience with EGFR Gene Mutation Analysis and Treatment of EGFR Positive Patients in the Years 2010 to 2015
Authors: Ondřej Venclíček, Petronela Venclíčková, Jana Skřičková, Jana Špeldová, Blanka Robešová, Dana Dvořáková, Svatopluk Richter, Mojmír Moulis, Jitka Hausnerová
Journal: Journal of Thoracic Oncology (2017)
M9 A high prevalence of obstructive sleep apnoea (OSA) in the severe/difficult to treat asthma (SDTA) population
Authors: SE Davies, N Cachada, A Turner, S Wharton, A Mansur
Journal: Thorax (2016)

<h3>Introduction</h3> An association between OSA and asthma has been demonstrated. The exact prevalence in the SDTA population is unknown. <h3>Aim</h3> To determine the prevalence and predictors of OSA in the SDTA population <h3>Methods</h3> All patients who attended a severe asthma regional centre between January 2013 and August 2016 with confirmed SDTA were asked to participate. All patients without a pre-existing OSA diagnosis had an overnight limited-channel sleep study. Patients underwent bioelectrical impedance measurements and completed the Epworth Sleepiness Score (ESS). <h3>Results</h3> 72 patients consented and were included in the analysis. 69.4% (n = 50) had OSA. 33.3% (n = 24) had a pre-existing diagnosis of OSA and 79% (n = 19) of this group were receiving Continuous Positive Airway Pressure (CPAP). 36% (n = 26) had a new diagnosis of OSA. 31% (n = 22) had OSA excluded with a negative sleep study. Mild OSA (Apnoea Hypopnoea Index(AHI) ≥5–14.9) = 31.9% (n = 23), moderate OSA (AHI ≥ 15–29.9) = 16.7% (n = 12), severe OSA (AHI ≥ 30) = 4.2% (n = 3). AHI was unknown for 16.6% (n = 12) with pre-existing OSA receiving CPAP from a specialist centre. The mean age was 47.7 years (18–73) and 72.2% (n = 52) were female. Mean Body Mass Index (BMI) was 32 (18.6–65.7). ESS was higher in the OSA group compared to the no-OSA group (11.0 vs 8.7, p = 0.091). The OSA group had significantly higher BMI (34.7 ± 8.00 vs 28.8 ± 9.62, p = 0.007) and body fat percentage (38.7 ± 12.37 vs 28.3 ± 14.03 fat%, p = 0.003) compared to the no-OSA group. The OSA group had a significantly higher incidence of hypercholesterolaemia compared to the no-OSA group (32.6% vs 8%, p = 0.0239). There was a higher incidence of diabetes (18.6% vs 8%, p = 0.0932), hypertension (27.9% vs 16%, p = 0.1643) and gastro-oesophageal reflux (60.5% vs 54.2%, p = 0.6189) in the OSA group. Blood eosinophil levels were significantly lower in the OSA group compared with the no-OSA group (0.23 ± 0.18 vs 0.39 ± 0.29 x10^9/L, p = 0.004). <h3>Conclusion</h3> A significant prevalence of OSA was noted in this SDTA population. BMI, percentage body fat and hypercholesterolaemia were the strongest predictors of OSA. Patients with OSA had significantly lower blood eosinophil levels when compared to the no-OSA group. Alternatives to eosinophilic inflammation as a driver for severe/difficult to treat asthma should always be considered.